Intellia reports case of liver toxicity in ATTR gene editing study
Intellia Therapeutics disclosed that one patient in a Phase 3 study of its gene editing treatment for a progressive heart disease experienced a serious case of elevated liver enzymes. The patient with transthyretin amyloid ...
Intellia Therapeutics disclosed that one patient in a Phase 3 study of its gene editing treatment for a progressive heart disease experienced a serious case of elevated liver enzymes.
The patient with transthyretin amyloid ...
